LKL INTERNATIONAL Berhad is enthusiastic about the fiscal year ending Sept 30, 2022 (FY22), owing to strong demand for medical/healthcare beds and accessories, as well as the planned launch of its lifestyle pharmacy.
LKL also plans to build its first unique lifestyle pharmacy chain shop in the fourth quarter of this year.
Its Executive Director Lim Ming Chang said that by entering the business-to-consumer (B2C) space through its new lifestyle pharmacy chain, the company intended to serve not just healthcare providers with its medical beds and peripherals but also the general public.
“Therefore, apart from our manufacturing and trading segments, our latest pharmacy retail chain space will allow us to capitalise on consumers’ increasingly health-conscious stance amidst the pandemic,” said Lim in a recent statement.
Due to expenditures for its personnel share option schemes,
LKL reported a net loss of RM1.9 million in the fifth quarter (Q5) ended July 31, 2021. In the fifth quarter, the company brought in RM13.5 million in sales.
Its manufacturing unit, which includes the provision of hospital beds and medical peripherals and accessories, generated RM8.6 million in sales representing 63.9 per cent of total revenue.
Meanwhile, earnings from the trade division, which includes medical peripherals and accessories and medical equipment, accounted for RM4.9 million, or 36.1 per cent of total revenue.
Local sales grew for RM12.5 million, or 92.8 per cent of the company’s
total revenue.
In Q5 2021, exports accounted for RM970,000 or 7.2 per cent of the company’s revenue, with Asia accounting for RM960,000 or 7.1 per cent, and the Middle East accounting for RM200,000 or 0.1 per cent.
The company had revenue of RM63.4 million and a net loss of RM5.7 million for the 15 months.
There are no comparison numbers in the financial report due to the change in financial year end. – The Health
